Founded in 1994, the company is engaged in de-addiction and pain management products in the domestic and international markets.
"We are setting up a R&D centre 'Navin Saxena Research and Technology' (NSRT), in association with Clinical research organisation - 'Quest Care' and a specialised manufacturing unit for transdermal patches at the Kandla SEZ," Rusan Pharma Chairman Navin Saxena told PTI after inaugurating the centre here.
"We are investing around Rs 200 crore in NSRT and QuestCare in the two phase programme by 2017, of which Rs 100 crore (are) already invested in phase I. It will be funded through internal accruals and bank loans.
Research at NSRT will focus on pain, addiction, central nervous system and orphan diseases, drug delivery and platform technologies and it also aims to undertake contract research and joint development projects.
More From This Section
QuestCare is a company's ultra modern bio-equivalence clinical research organisation, which was set up as JV with Chennai based Quest Life Sciences, he said.
The company also proposes to invest in further innovation for new targeted delivery drugs for breast cancer, naltrexone implant for alcohol abuse, dengue and Zica viruses.
It has also announced the agreement with Brazil Health Ministry for their program for smoking cessation.
"Rusan and NSRT have dedicated to develop and deliver
innovative products to the patients. And we are the largest and reputed suppliers of life saving drugs like Buprenorphine, Methadone and anti-TB drugs to Russia, CIS, South Africa, Kenya, Mauritius, Nepal and Myanmar," company's Managing Director Kunal Saxena said.
A pre-inaugural event saw the signing of a memorandum of understanding between NSRT, Moscow State University (Russia), Symbiosis College Pune, The Maharaja Sayajirao University of Baroda and IIT Kanpur.